Results for proteasom translation from Danish to English

proteasom
proteasome

bortezomib er en proteasom-hæmmer.
bortezomib is a proteasome inhibitor.

bortezomib er meget selektivt for proteasom.
bortezomib is highly selective for the proteasome.

virkningsmekanisme bortezomib er en proteasom- hæmmer.
mechanism of action bortezomib is a proteasome inhibitor.

hæmning af proteasom resulterer i cellecyklusstop og apoptose.
inhibition of the proteasome results in cell cycle arrest and apoptosis.

26s-proteasom er et stort proteinkompleks, som nedbryder ubiquitinerede proteiner.
the 26s proteasome is a large protein complex that degrades ubiquitinated proteins.

den er specifikt designet til at hæmme chymotrypsinlignende aktivitet ved 26s-proteasom i pattedyrceller.
it is specifically designed to inhibit the chymotrypsin-like activity of the 26s proteasome in mammalian cells.

i koncentrationer på 10 µm hæmmer bortezomib ikke nogen af en lang række screenede receptorer og proteaser og er mere end 1500 gange så selektivt for proteasom end for det næste foretrukne enzym.
at 10 µm concentrations, bortezomib does not inhibit any of a wide variety of receptors and proteases screened and is more than 1500-fold more selective for the proteasome than for its next preferable enzyme.

i koncentrationer på 10 µm hæmmer bortezomib ikke nogen af en lang række screenede receptorer og proteaser og er mere end 1.500 gange så selektivt for proteasom end for det næste foretrukne enzym.
at 10 m concentrations, bortezomib does not inhibit any of a wide variety of receptors and proteases screened and is more than 1,500-fold more selective for the proteasome than for its next preferable enzyme.

ubiquitin-proteasom-vejen spiller en vigtig rolle i reguleringen af omsætningen af specifikke proteiner, som derved opretholder homeostasen inde i cellerne.
the ubiquitin-proteasome pathway plays an essential role in regulating the turnover of specific proteins, thereby maintaining homeostasis within cells.

forsøg har påvist, at bortezomib er cytotoksisk over for en række cancercelletyper, og at cancerceller er mere følsomme over for proapoptotiske virkninger af proteasom- hæmning end normale celler.
experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types and that cancer cells are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells.

kinetikken ved proteasomhæmning blev vurderet in vitro, og det blev påvist, at bortezomib adskiller sig fra proteasom med et t½ på 20 minutter, hvilket påviser, at proteasomhæmning ved hjælp af bortezomib er reversibel.
the kinetics of proteasome inhibition were evaluated in vitro, and bortezomib was shown to dissociate from the proteasome with a t½ of 20 minutes, thus demonstrating that proteasome inhibition by bortezomib is reversible.

hæmning af 26s- proteasom forhindrer denne målretteede proteolyse og påvirker multiple signalleringskaskader i cellen, hvilket til sidst resulterer i cancer- celle- død.
inhibition of the 26s proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.

ansøgeren præsenterer resultaterne fra det planlagte fase i/ ii kliniske forsøg (protokollen til gennemgang hos nci), der har til formål at udelukke muligheden for, at bortezomib- behandling kan øge risikoen for amyloidose og/ eller kan have en uheldig virkning på dets udvikling og manifestation i organerne som en konsekvens af proteasom- hæmning.
the applicant will present the results from the planned phase i/ ii clinical trial (protocol under review at nci) aimed at ruling out the possibility that secondary to proteasome inhibition bortezomib treatment may increase the risk of amyloidosis and/ or may have an adverse impact on its progression and organ manifestations.